Results 221 to 230 of about 20,698 (251)
ABSTRACT Introduction Cardiovascular (CV) outcomes of Glucagon‐like peptide‐1 (GLP‐1)–based medicines among people with overweight and obese (OW/OB) population have been investigated by meta‐analyses of randomized controlled trials (RCTs), but an overall summary is lacking.
Muhammed Rashid +6 more
wiley +1 more source
Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis. [PDF]
Lu D, Li N, Yuan Z, Gao Y.
europepmc +1 more source
One Size Fits None: Developing a Person‐Centered Approach to Weight Management in Older Adults
Journal of the American Geriatrics Society, EarlyView.
Aruna V. Josyula +6 more
wiley +1 more source
Sweetening the Odds: Can Newer Glucose-Lowering Drugs Bend the Arc of Epileptogenesis? [PDF]
Zawar I.
europepmc +1 more source
Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review. [PDF]
van Maren SJF +5 more
europepmc +1 more source
From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD. [PDF]
Chrysavgis L, Cholongitas E.
europepmc +1 more source
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. [PDF]
Ding M +10 more
europepmc +1 more source
A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy. [PDF]
Ampofo E +3 more
europepmc +1 more source

